Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

• Published in: The lancet oncology Vol. 19; no. 7; pp. 953 - 964
• Main Authors: Moreau, Philippe, Mateos, Maria-Victoria, Berenson, James R, Weisel, Katja, Lazzaro, Antonio, Song, Kevin, Dimopoulos, Meletios A, Huang, Mei, Zahlten-Kumeli, Anita, Stewart, A Keith
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.07.2018; Elsevier Limited
• Subjects: Bortezomib; Congestive heart failure; Dexamethasone; Hematology, Oncology, and Palliative Medicine; Hypertension; Immunomodulation; Inhibitor drugs; Intravenous administration; Lysis; Motivation; Multiple myeloma; Patients; Population; Proteasome inhibitors; Respiratory distress syndrome; Sepsis; Targeted cancer therapy; Thrombocytopenia; Tumors
• ISSN: 1470-2045; 1474-5488; 1474-5488
• DOI: 10.1016/S1470-2045(18)30354-1

Twice a week carfilzomib at 27 mg/m2 is approved for treatment of relapsed or refractory multiple myeloma. Phase 1/2 CHAMPION-1, the first study exploring once-weekly carfilzomib dosing, established the maximum tolerated dose at 70 mg/m2 in combination with dexamethasone. We aimed to compare progres...